Indias drugs controller approves  COVID vaccines
2021-01-03 15:26
Vials of AstraZenecas COVISHIELD, coronavirus disease COVID vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, India, Nov , .PhotoAgencies    NEW DELHI  The Drugs Controller General of India DCGI on Sunday gave its approval to two vaccines for emergency use. Addressing media, DCGI Dr. V.G. Somani said the permission was granted for restricted use in emergency situation. He said that the Subject Expert Committee SEC of Central Drugs Standard Control Organisation CDSCO met on Jan  and Jan , making recommendations in respect of proposal for restricted emergency approval of COVID virus vaccine of Serum Institute of India SII and Bharat Biotech as well as Phase  clinical trial of Cadila Healthcare Limited. The SII, situated in southwestern city of Pune, presented a Recombinant Chimpanzee Adenovirus vector vaccine Covishield encoding the SARSCoV Spike S glycoprotein with technology transfer from AstraZenecaOxford University, said a DCGI statement. The Subject Expert Committee SEC has reviewed the data on safety and immunogenicity of the vaccine and recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains. The clinical trial ongoing within the country by the firm will continue, he told media.